- Startseite
- Klinik
- Direktor & Team
Liu SK, Bham SA, Fokas E, et al. Delta-like ligand 4-notch blockade and tumor radiation response. Journal of the National Cancer Institute 2011;103:1778-98.
Fokas E, Im JH, et al. Dual inhibition of the PI3K/mTOR pathway increases tumor radiosensitivity by normalizing tumor vasculature. Cancer Research 2012;72:239-48.
Fokas E, Liersch et al. Tumor regression grading after preoperative chemoradiotherapy for locally advanced rectal carcinoma revisited: updated results of the CAO/ARO/AIO-94 trial. Journal of Clinical Oncology 2014;32:1554-62.
Ashton TM, Fokas E, et al. The anti-malarial atovaquone increases radiosensitivity by alleviating tumour hypoxia. Nature Communications 2016;7:12308.
Azad A, Yin Lim S,…., Fokas E. PD-L1 blockade enhances response of pancreatic ductal adenocarcinoma to radiotherapy. EMBO Mol Med 2017;9:167-80.
Fokas E, Ströbel P, et al. Tumor regression grading after preoperative chemoradiotherapy as prognostic factor and individual-level surrogate for disease-free survival in rectal cancer. Journal of the National Cancer Institute 2017;109(12).
D'Costa Z, Jones K,…, Fokas E. Gemcitabine-Induced TIMP1 Attenuates Therapy Response and Promotes Tumor Growth and Liver Metastasis in Pancreatic Cancer. Cancer Research 2017;77:5952-5962.
Kitz J*, Fokas E*, et al. The plane of total mesorectal excision is prognostic in rectal cancer: Results of the CAO/ARO/AIO-04 open-label, randomized, phase 3 trial. JAMA Surgery 2018;153:e181607. *joint first authors.
Fokas E, Fietkau R, et al. Neoadjuvant rectal score as individual-level surrogate for disease-free survival in rectal cancer in the CAO/ARO/AIO-04 randomized phase 3 trial. Annals of Oncology 2018;29:1521-1527.
Hofheinz RD, Arnold D, Fokas E, et al. Impact of age on the efficacy of oxaliplatin in the preoperative chemoradiotherapy and adjuvant chemotherapy of rectal cancer: a post hoc analysis of the CAO/ARO/AIO-04 phase III trial. Annals of Oncology 2018;29:1793-99.
Fokas E, Allgauer M, et al. Randomized Phase II Trial of Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: CAO/ARO/AIO-12. Journal of Clinical Oncology 2019;37:3212-3222.
Ludmir EB, Fuller CD,..., Rödel C, Fokas E. Sex-Based Disparities Among Cancer Clinical Trial Participants. Journal of the National Cancer Institute 2019;112:211-213.
Diefenhardt M, Ludmir EB,..., Fokas E. Association of sex with toxic effects, treatment adherence, and oncologic outcomes in the CAO/ARO/AIO-94 and CAO/ARO/AIO-04 Phase 3 randomized clinical trials of rectal cancer. JAMA Oncology 2019;6:294-6.
Fokas E, Glynne-Jones R, et al. Outcome measures in multimodal rectal cancer trials. Lancet Oncology 2020;21:e252-e264.
Diefenhardt M, Ludmir EB,.., Fokas E. Association of Treatment Adherence With Oncologic Outcomes for Patients With Rectal Cancer: A Post Hoc Analysis of the CAO/ARO/AIO-04 Phase 3 Randomized Trial. JAMA Oncology 2020;
Fokas E, Appelt A, et al. International consensus recommendations on key outcome measures for organ preservation after (chemo)radiotherapy in patients with rectal cancer. Nature Review Clinical Oncology 2021;12:805-816.
Fokas E, Schlenska-Lange A,..., Rödel C. Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer: Long-term Results of the CAO/ARO/AIO-12 Randomized Clinical Trial. JAMA Oncology 2022:8;e215455.
Nicolas A, Pesic M,..., Fokas E, Greten FR. Inflammatory fibroblasts mediate resistance to neoadjuvant therapy in rectal cancer. Cancer Cell 2022;40:1-17.
Fokas E, Rodel C, et al. Disease-free survival as the endpoint in multimodal rectal cancer trials: have we got this right? Lancet Gastroenterology Hepatology 8:962-964, 2023.
Diefenhardt M, Martin D,…, Fokas E. Overall Survival After Treatment Failure Among Patients With Rectal Cancer. JAMA Network Open 6:e2340256, 2023.
Fokas E, Glynne-Jones R, et al. Early efficacy endpoints in neoadjuvant rectal cancer trials: Surrogacy revisited. Journal of Clinical Oncology 42(8):872-875, 2024.
Kagawa Y, Smith JJ, Fokas E, et al. Future direction of total neoadjuvant therapy for locally advanced rectal cancer. Nature Reviews Gastroenterology Hepatology 21(6):444-455. doi: 10.1038/s41575-024-00900-9, 2024
Williams H*, Fokas E*, et al. Survival Among Patients Treated with Total Mesorectal Excision or Selective Watch-and-Wait After Total Neoadjuvant Therapy: A Pooled Analysis of the CAO/ARO/AIO-12 and OPRA Randomized Phase II Trials. Annals of Oncology. S0923-7534(25)00010-9, 2025. *joint first author.
Gani C, Fokas E, et al. Organ preservation after total neoadjuvant therapy for locally advanced rectal cancer (CAO/ARO/AIO-16): an open-label, multicentre, single-arm, phase 2 trial. Lancet Gastroenterology Hepatology 2025, in press.
Hofheinz R, Fokas E, et al. Rectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Annals of Oncology 2025, in press.
Rödel F, Fleischmann M, …., Fokas E. Emerging advances and future opportunities in the molecular and therapeutic landscape of anal cancer. Nature Reviews Clinical Oncology 2025, in press.